Acadia Pharma (ACAD) Q2 Revs of $115.2M; Tops EPS by 4c
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $26.41 +0.08%
Revenue Growth %: +19.3%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +19.3%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.27), $0.04 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $115.2 million versus the consensus estimate of $126.15 million.
GUIDANCE:
Acadia Pharma sees Q3 2021 revenue of $480-515 million, versus the consensus of $527.7 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KB Home (KBH) Tops Q3 EPS by 16c
- Sun Communities completes $1.03B sale of Park Holidays to Aermont
- Jefferies Starts Frencken Group Ltd. (FRKN:SP) at Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
